Analisis Minimalisasi Biaya (AMiB) Antihipertensi Irbesartan dengan Candesartan pada Pasien Hipertensi Rawat Jalan
- Nurlaela Nurlaela Universitas Harapan Bangsa, Purwokerto, Indonesia
-
Fauziah Fauziah
*
Universitas Harapan Bangsa, Purwokerto,
Indonesia
- Khamdiyah Indah K Universitas Harapan Bangsa, Purwokerto, Indonesia
- Ikhwan Yuda Kusuma Universitas Harapan Bangsa, Purwokerto, Indonesia (*) Corresponding Author
Abstract
Cost minimization of antihypertensive therapy is very essential to optimize patient care and allocation of hospital resources. This study aimed to compare the most cost-minimized cost of irbesartan and candesartan therapy treatment in hypertensive patients at Goeteng Taroenadibrata Purbalingga in the periods January to December 2023. The research method used quantitative with a retrospective approach. Data were analyzed using normality kormogorov smirnov test and continued by mann whitney test. population in this were hypertensive patients at Goeteng Taroenadibrata Purbalingga with a sample of 100 hypertensive patients.The results showed that out of 100 samples, 37 samples used irbesartan and 63 candesartan samples with an average total direct medical cost of antihypertensive treatment, laboratory costs and consultation costs required by patients using irbesartan therapy Rp. 158,665, and candesartan Rp. 116,874. Statistical analysis has a p-value that shows a significant difference between irbesartan treatment and candesartan treatment. the conclusion in this study is that the most cost-minimizing antihypertensive therapy is the candesartan group compared to the irbesartan group. Further research is needed to analyze a broader CMA of blood pressure control and comorbid diseases.
Downloads
References
Akbar, M., Ardana, M., & Kuncoro, H. (2018). Analisis Minimalisasi Biaya (Cost-Minimization Analysis) Pasien Gastritis Rawat Inap di RSUD Abdul Wahab Sjahranie Samarinda. Proceeding of Mulawarman Pharmaceuticals Conferences, 7, 14–21. https://doi.org/10.25026/mpc.v7i1.285
Andra, C. (2016). The Different Therapeutic Choices with ARBs . Which One to Give ? When ? Why ? 255–266. https://doi.org/10.1007/s40256-016-0165-4
Bambungan. Y.M., R.A., O., & Satibi. (2022). Analisis Biaya Pengobatan Hipertensi Pada Pasien Rawat Inap Di Rsud Sorong. Jurnal Electronik, VII(2), 73–76. http://2trik.jurnalelektronik.com/index.php/2trik
Baroroh, F., & Sari, A. (2018). Cost Effectiveness Analysis Therapy Combination of Candesartan-Amlodipine and Candesartan-Diltiazem on Hypertensive Outpatients. PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia), 14(2), 188. https://doi.org/10.30595/pharmacy.v14i2.1952
BPJS Kesehatan. (2018). Statistik Jaminan Kesehatan Nasional 2014-2018. https://djsn.go.id/files/dokumen/Dokumen%20Kajian/202104151516Statistik%20JKN%202014-2018_PDF%20E-Book_Cetakan%20Pertama(DJSN%20-%20BPJS%20Kesehatan).pdf.
Dewi, M. I. K., Prabowo, W. C., & Rusli, R. (2019). Analisis Biaya Minimal Penggunaan Antihipertensi Di Rumah Sakit Umum Daerah Kota Bontang. Proceeding of Mulawarman Pharmaceuticals Conferences, 9, 27–31. https://doi.org/10.25026/mpc.v9i1.338
Dewi, S. S. S., Futri, L. C., & Ramadhini, D. (2021). Pendidikan Kesehatan Tentang Pemenuhan Gizi Seimbang Pada Bayi Dan Balita di Desa Joring Lombang Kecamatan Padangsidimpuan Angkola Julu Kota Padangsidimpuan. Jurnal Pengabdian Masyarakat Aufa (JPMA), 3(3), 148–152. https://jurnal.unar.ac.id/index.php/jamunar/article/view/540
Dinas Kesehatan Jawa Tengah. (2022). Profil Kesehatan Jawa Tengah 2011. https://dinkesjatengprov.go.id/v2018/dokumen/Buku_Profil_Kesehatan_2022/mobile/index.html.
Dinas Kesehatan Purbalingga. (2021). Profil Kesehatan Kabupaten Purbalingga. Angewandte Chemie International Edition, 6(11), 951–952., 15(2), 1–23.
Gultom, R & Silvia, M. (2022). Cost Minimalization Analysis (Cma) Penggunaan Obat Antihipertensi Golongan Calcium Channel Blocker Kombinasi Angiotensin Receptor Blocker Pada Pasien Hipertensi Di Rsu Imelda Pekerja Indonesia Medan. JIFI (Jurnal Ilmiah Farmasi Imelda), 5(2), 51–56. https://doi.org/10.52943/jifarmasi.v5i2.771
GW Primer, A. L. (2015). Factors Affecting the Treatment of Hypertension in the Elderly Compliance Patronage PHC Klungkung. Bali: Medical Education Program at Udayana University Medical Faculty.
Haldar, R. N. (2013). Global Brief on Hypertension: Silent Killer, Global Public Health Crisis. Indian Journal of Physical Medicine and Rehabilitation, 24(1), 2–2. https://doi.org/10.5005/ijopmr-24-1-2
Hapsari, W. S., & Herma, F. A. (2017). Pola Penggunaan Obat Antihipertensi Pada Pasien Hipertensi Rawat Jalan Bpjs Di Rsud Krt Setjonegoro Wonosobo. Jurnal Farmasi Sains Dan Praktis, III(2).
Ikawati, Z. (2014). farmakologi molekuler target aksi obat dan mekanisme molekulernya. Yogyakarta: Gadjah Mada University Press.
Indah, K. (2022). Analysis Of Antihypertension Therapy In Hypertension BPJS Patients In Purbalingga District. Jurnal Cakrawala Ilmiah, 2(4), 1283–1300.
Katherine F Croom 1, Monique P Curran, Karen L Goa, C. M. P. (2012). Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Pubmed. https://pubmed.ncbi.nlm.nih.gov/15101793/
Kemenkes. (2021). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Hipertensi Dewasa. Kementerian Kesehatan RI, 1–85.
Klabunde, M., Collado, D., & Bohon, C. (2017). Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review. Journal of Psychiatric Research, 94(3), 36–46. https://doi.org/10.1016/j.amepre.2017.06.020.Cost-effectiveness
Lee, W., Kang, J., Park, J. B., Seo, W. W., Lee, S. Y., Lim, W. H., Jeon, K. H., Hwang, I. C., & Kim, H. L. (2023). Long-term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real-world database: A retrospective cohort study. Health Science Reports, 6(2). https://doi.org/10.1002/hsr2.1056
Marbun, M., Selida, A., Wardiah, R. (2023). Gambaran Cost Of Iillness dari Perspektif Pasien Hipertensi Rawat Jalan. Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal, 14, 125–136.
Mashuri, Y. A., Ng, N., & Santosa, A. (2022). Socioeconomic disparities in the burden of hypertension among Indonesian adults - a multilevel analysis. Global Health Action, 15(1). https://doi.org/10.1080/16549716.2022.2129131
Meher, M., Pradhan, S., & Pradhan, S. R. (2023). Risk Factors Associated With Hypertension in Young Adults : A Systematic Review. 15(4). https://doi.org/10.7759/cureus.37467
Muna, L., Melviani., Syamsu, E. (2023). Cost Minimization Analysis ( CMA ) Penggunaan Obat Captopril dan Lisinopril pada Pasien Hipertensi di RSUD Sultan Suriansyah Banjarmasin. Jurnal Surya Medika (JSM), 9(2), 18–25.
Nakamura, M., Sasai, N., Hisatome, I., & Ichida, K. (2014). Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clinical Pharmacology: Advances and Applications, 6(1), 79–86. https://doi.org/10.2147/CPAA.S61462
Nugraheni, D. A., & Andayani, T. M. (2015). Cost - Minimization Analysis Kaptopril Dibandingkan Lisinopril pada Pasien Hipertensi Rawat Jalan. Jurnal Farmasi Indonesia, 12(2), 179–189.
Okpechi. (2010). Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction. Integrated Blood Pressure Control, 45. https://doi.org/10.2147/ibpc.s9963
Paul, G. K., Karmoker, K. K., Sen B, Hussain, M. Z., Hasan, M. S & Khan, M. K. (2020). Risk factors for hypertension in young adults of Bangladesh. https://pubmed.ncbi.nlm.nih.gov/31915334/ Mymensingh Med J. 2020;29:43–47. 29. 43-47.
PERHI. (2019). Konsensus Penatalaksanaan Hipertensi 2019. Indonesian Society Hipertensi Indonesia, 1–90.
Piťha, J., Vaněčková, I., & Zicha, J. (2023). Hypertension after the Menopause: What Can We Learn from Experimental Studies? Physiological Research, 72, 91–112. https://doi.org/10.33549/physiolres.935151
Rahayu, D., Kusuma, N., Amarullah, A., Rahmawati, D., Kesehatan, F. I., Anwar, U., & Sidoarjo, M. (2023). Cost Minimization Analysis Pasien JKN Rawat Jalan Penyakit Hipertensi di RS “ X ” Kota Surabaya. Journal of Health Management Research, 2(2), 46–55.
Riset Kesehatan Dasar (Riskesdas). (2018). Badan Penelitian dan pengembangan Kesehatan Kementerian RI Tahun 2018. In Lembaga Penerbit Balitbangkes.
Roslandari, L. M. W., Illahi, R. K., & Lawuningtyas, A. (2020). Hubungan Antara Dukungan Keluarga dengan Tingkat Kepatuhan Pengobatan Pasien Hipertensi Rawat Jalan Pada Program Pengelolaan Penyakit Kronis. Pharmaceutical Journal of Indonesia, 5(2), h 131-139.
Rumi, A., & Budiyanto, T. D. C. (2023). Effect of Candesartan Usage on Uric Acid Levels. Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal), 9(2), 257–269. https://doi.org/10.22487/j24428744.2023.v9.i2.15592
Sabbatini, A. R., & Kararigas, G. (2020). Estrogen-related mechanisms in sex differences of hypertension and target organ damage. Biology of Sex Differences, 11(1), 1–17. https://doi.org/10.1186/s13293-020-00306-7
Sasaki, N., Yamamoto, H., Ozono, R., Fujiwara, S., & Kihara, Y. (2018). Association of N-Terminal Pro B-Type Natriuretic Peptide With Blood Pressure and Pulse Pressure in Elderly People ―. 82(August), 2049–2054. https://doi.org/10.1253/circj.CJ-18-0031
Schutte, A. E., Srinivasapura Venkateshmurthy, N., Mohan, S., & Prabhakaran, D. (2021). Hypertension in Low- and Middle-Income Countries. Circulation Research, 128(7), 808–826. https://doi.org/10.1161/CIRCRESAHA.120.318729
Theodoridis, T., & Kraemer, J. (2021). Guideline for the pharmacological treatment of hypertension in adults.
Ulfa, N. M., Ernawati, L., P., Kurniawanto, R., & Indrawati, A. (2019). Profil Penggunaan Obat Antianemia, Antihipertensi, dan Antidiabetik pada Pasien Penyakit Ginjal Kronik di Salah Satu Rumah Sakit Wilayah Surabaya Selatan. Pharmaceutical Journal of Indonesia, 16(02), 296–306.
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., Wainford, R. D., Williams, B., & Schutte, A. E. (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75(6), 1334–1357. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
Utari, A. B., & Rochmah, T. N. (2019). the Analysis of Hypertension Burden Disease in the Community of Kediri District. Indonesian Journal of Public Health, 14(2), 138–149. https://doi.org/10.20473/ijph.v14i2.2019.138-149
Van Rodijnen, W. F., Van Lambalgen, T. A., Van Teijlingen, M. E., Tangelder, G. J., & Ter Wee, P. M. (2001). Comparison of the AT1-receptor blockers candesartan, irbesartan and losartan for inhibiting renal microvascular constriction. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2(SUPPL. 1). https://doi.org/10.1177/14703203010020013601
Veisani, Y., Jenabi, E., Nematollahi, S., Delpisheh, A., & Khazaei, S. (2019). The role of socio-economic inequality in the prevalence of hypertension in adults. Tabriz University of Medical Sciences, 11(2), 116–120. https://doi.org/10.15171/jcvtr.2019.20
Wang, Y., Johnston, K., Popoff, E., Myren, K., Faria, C., Tomazos, I., Wang, Y., Johnston, K., Popoff, E., & Myren, K. (2020). A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. Journal of Medical Economics, 23(12), 1503–1515. https://doi.org/10.1080/13696998.2020.1831519
Wierzejska, E., Giernaś, B., Lipiak, A., Karasiewicz, M., & Cofta, M. (2020). Systematic review / Meta-analysis A global perspective on the costs of hypertension : a systematic review. Arch Med Sci, 16, 1078–1091.
World Health Organization (WHO). (2023). Global Report on Hypertension. https://www.who.int/publications/i/item/9789240081062.
Yulanda, G & Lisisnawati, R. (2017). Penatalaksanaan Hipertensi Primer. Jurnal Majority, 6(1), 25–33.
Bila bermanfaat silahkan share artikel ini
Berikan Komentar Anda terhadap artikel Analisis Minimalisasi Biaya (AMiB) Antihipertensi Irbesartan dengan Candesartan pada Pasien Hipertensi Rawat Jalan
Pages: 1-8
Copyright (c) 2024 Fauziah Fauziah, Nurlaela Nurlaela
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (Refer to The Effect of Open Access).
